Vanguard Group Inc. Reduces Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Vanguard Group Inc. cut its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,836,257 shares of the medical equipment provider's stock after selling 12,069 shares during the quarter. Vanguard Group Inc. owned 6.11% of BioLife Solutions worth $73,629,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions in the 4th quarter worth approximately $26,000. 1620 Investment Advisors Inc. lifted its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares during the period. Smartleaf Asset Management LLC grew its position in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after buying an additional 950 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of BioLife Solutions during the fourth quarter valued at approximately $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in BioLife Solutions in the fourth quarter worth $201,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

Analysts Set New Price Targets

BLFS has been the subject of several research reports. StockNews.com upgraded shares of BioLife Solutions from a "sell" rating to a "hold" rating in a report on Tuesday, April 8th. Benchmark reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. HC Wainwright lifted their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $31.17.

Remove Ads

Insider Buying and Selling at BioLife Solutions

In other news, CMO Todd Berard sold 8,902 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $201,719.32. Following the sale, the chief marketing officer now directly owns 135,956 shares in the company, valued at $3,080,762.96. The trade was a 6.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sarah Aebersold sold 1,091 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00. Following the sale, the insider now owns 58,816 shares in the company, valued at $1,470,400. This represents a 1.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,127 shares of company stock valued at $1,676,533 in the last three months. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Stock Performance

Shares of BLFS stock traded up $0.07 during trading hours on Tuesday, reaching $22.15. 231,179 shares of the company traded hands, compared to its average volume of 374,582. The firm has a 50-day moving average price of $24.95 and a 200 day moving average price of $25.33. The company has a market cap of $1.04 billion, a P/E ratio of -20.90 and a beta of 1.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same period in the prior year, the business posted ($0.21) earnings per share. As a group, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.